Mendus AB is a Swedish company dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life.

The company leverages its expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile.

We spoke with the company's CEO, Erik Manting, at Bio-Europe.

➡ Subscribe to our newsletter: https://bit.ly/3kHyfKc
➡ Get more biotech news:
Official site: https://bit.ly/3OJgYzi
Linkedin: https://www.linkedin.com/company/5312453
Twitter: https://twitter.com/Labiotech_eu
Facebook: https://www.facebook.com/Labiotech.eu
Instagram: https://www.instagram.com/labiotech.eu/

About Labiotech.eu:
Labiotech.eu is an online publication covering the global biotech industry, with a mix of news and in-depth analysis. Updated daily, the site also includes a weekly podcast.

#biotech #immunotherapy #cancertreatment